A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 1934-1940

  Woodward, M ^a,b   Lowe, G D O ^c   Francis, L M A ^b   Rumley, A ^c   Cobbe, S M ^c   Bain, R ^d   Dean, J ^e   Fulcher, R ^f   Gershlick, A ^g   Haywood, G ^h   Jones, C ⁱ   Kamalvand, K ^j   Levy, R ^k   Lip, G ^l   Mattu, R ^m   Murphy, C ⁿ   Murtagh, J G ^o   Pye, M ^p   Qureshi, N ^q  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MIS Consultants Pty Ltd   (Australia)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^e ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^f NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

^g GLENFIELD HOSPITAL   (United Kingdom)

^h DERRIFORD HOSPITAL   (United Kingdom)

ⁱ PRINCESS OF WALES HOSPITAL   (United Kingdom)

^j WILLIAM HARVEY HOSPITAL   (United Kingdom)

^k WYTHENSHAWE HOSPITAL   (United Kingdom)

^l CITY HOSPITAL   (United Kingdom)

^m WALSGRAVE HOSPITAL   (United Kingdom)

ⁿ ST RICHARD S HOSPITAL   (United Kingdom)

^o BELFAST CITY HOSPITAL   (United Kingdom)

^p YORK HOSPITAL   (United Kingdom)

^q WARWICK HOSPITAL   (United Kingdom)

more..

Author keywords

Coagulation; Coronary heart disease; Inflammation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INDIGESTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REFERENCE VALUE; RISK FACTOR; THORAX PAIN; THROMBOSIS;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD VISCOSITY; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS; TICLOPIDINE;

EID: 19944430180     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01017.x     Document Type: Article

References (26)

1. Libby P. Molecular base of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
2. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996; 94: 2013-20.
3. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002, 324: 71-86.
4. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparins, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336: 847-60.
5. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest 2001; 119: 228s-252s.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000; 321: 199-204.
7. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erthryocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21: 515-20.
8. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-7.
9. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. Von Willebrand factor and coronary heart disease: new prospective study and meta-analysis. Eur Heart J 2002; 23 1764-70.
10. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study. Br J Haematol 1999; 105: 110-6.
11. Meade TW, Cooper JC, Stirling Y, Howarth DJ, Ruddock V, Miller G.J. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-7.
12. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79: 129-33.
13. Haines AP, Howarth DJ, North WRS, Goldenberg E, Stirling Y, Meade TW, Rafferty EB, Millar Craig MW. Haemostatic variables and the outcome of myocardial infaretion. Thromb Haemost 1983; 50: 800-3.
14. Lagrand WK, Visser CA, Hermens WT, Niessen HWM, Verheugt FWA, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 1999; 1000: 96-102.
15. Lowe GDO. Blood rheology, haemostasis and vascular disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis, 3rd edn. Edinburgh: Churchill Livingstone, 1994: 1169-88.
16. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85 584-95.
17. Hankey G, Sudlow C, Dunbabin DW. Thioenopyridines versus aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779-84.
18. Boisseau MR, Mazoyer E, Ripoll L, Drouet L. How does ticlopidine treatment lower plasma fibrinogen? Thromb Res 1994; 75: 361-70.
19. Woodward M. Epidemiology: Study Design and Data Analysis Boca Raton: Chapman & Hall/CRC Press, 1999.
20. von Clauss A. Gerinnungs-physiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
21. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors; results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
22. Lowe GDO, Rumley A, Sweetnam P, Yarnell JWG, Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 2001; 85: 822-7.
23. Petrukhina GN, Remov MN, Makarov VA, Gandel VG. Effect of chronic administration of epaden and acetylsalicylic acid on the antithrombotic potential of blood vessel walls in rabbits. Eksp Klin Farmakol 2002; 65: 46-52 (Russian).
24. Slavina NN, Averkov OV, Dobrovolskii AB, Gratsianskii NA. Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel. Kardiologiia 2003; 43: 4-11 (Russian).
25. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, Johnston M, Yusuf S. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002; 23 1771-9.
26. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.